NYSE: STVNStevanato Group Spa Stock
$27.52+0.21 (+0.77%)
Updated Apr 25, 2024
STVN Price
$27.52
Fair Value Price
N/A
Market Cap
$8.13B
52 Week Low
$23.00
52 Week High
$36.30
P/E
46.02x
P/B
6.61x
P/S
6.69x
PEG
51.22x
Dividend Yield
N/A
Revenue
$1.18B
Earnings
$161.81M
Gross Margin
31.3%
Operating Margin
20.35%
Profit Margin
13.4%
Debt to Equity
0.83
Operating Cash Flow
$117M
Beta
1.02
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
STVN Overview
Stevanato Group S.p.A. provides drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It offers glass containers (under its historic Ompi brand), plastic components for diagnostics and medical devices, contract manufacturing services for drug delivery systems, and inspection, assembly and packaging machines. In support of drug development, the company provides analytical services and tests that study the interaction between containers, drugs, and their integration into delivery systems. Stevanato Group S.p.A. was founded in 1949 and is headquartered in Piombino Dese, Italy.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how STVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STVN ($27.52) is trading above its intrinsic value of $3.47, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STVN is poor value based on its earnings relative to its share price (46.02x), compared to the US market average (40.97x)
P/E vs Market Valuation
STVN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more STVN due diligence checks available for Premium users.
Be the first to know about important STVN news, forecast changes, insider trades & much more!
STVN News
Valuation
STVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
46.02x
Industry
47.92x
Market
40.97x
STVN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
STVN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
STVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.61x
Industry
3.49x
STVN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STVN price to earnings growth (PEG)
For valuing profitable companies with growth potential
STVN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
STVN's financial health
Profit margin
Revenue
$356.3M
Net Income
$50.3M
Profit Margin
14.1%
STVN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STVN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.3B
Liabilities
$1.0B
Debt to equity
0.83
STVN's short-term assets ($936.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STVN's short-term assets ($936.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STVN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
STVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$11.3M
Investing
-$71.5M
Financing
$66.5M
STVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STVN vs Medical Stocks
Stevanato Group Spa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.